Clinical trials
Therapy clinical trials
Below are recruiting therapy clinical trials, each written for real people, not researchers. We’re tracking 7,182 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03888950Recruiting
Interim PET-CT scan to assess anti-PD-1 treatment in melanoma
This study checks an “interim” whole-body scan (PET-CT) partway through treatment to see how well anti-PD-1 immunotherapy (nivolumab or pembrolizumab) is working for advanced melanoma. It may help doctors better understand early treatment response and guide next steps.
Nice, CHU de NICEAges 18 years+ - NCT04700878Recruiting
Compassion course study for healthcare workers under stress
This trial tests whether a digital “compassion” training course can reduce stress in people who work directly with patients. You may be offered the course (or not, depending on random assignment) to see if it improves how you feel at work.
Vaxjo, Kronoberg CountyAges 20 years+ - NCT07281417RecruitingPhase 2
Testing adding cemiplimab to chemo before surgery for sinus cancer
This trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery helps treat sinonasal squamous cell carcinoma. The goal is to see if this combination reduces tumors more effectively than chemotherapy alone.
Irvine, CaliforniaAges 18 years+ - NCT07282275Recruiting
Does ongoing green light therapy improve health outcomes?
This trial looks at what happens when people continue using green light therapy over time. It aims to see if ongoing use leads to better health results.
New York, New YorkAges 18 years+ - NCT07285785RecruitingPhase 4
Rifaximin for children with acute diarrhea
This study tests whether a medicine called rifaximin, taken along with oral rehydration solution, helps children aged 6 to 11 recover faster from acute (short-lasting) diarrhea that is likely caused by a bacterial infection. The study compares rifaximin plus oral rehydration versus oral rehydration alone.
Lynwood, CaliforniaAges 6–12 - NCT07283367RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
GuangzhouAges 18 years+ - NCT07282847RecruitingPhase 1/Phase 2
Gene therapy for adults with Pompe disease
This study tests a one-time gene therapy (AB-1009) for adults with late-onset Pompe disease. It aims to see if the treatment is safe and improves muscle and breathing function.
Phoenix, ArizonaAges 18–65 - NCT07282574RecruitingPhase 2
Study of an add-on drug for progressive multiple sclerosis
This trial tests whether adding a new medication, RO7268489, to the standard treatment ocrelizumab (Ocrevus) can help people with progressive forms of multiple sclerosis (MS) by slowing disability progression. The trial will evaluate the safety and effectiveness of this combination approach.
Camperdown, New South WalesAges 18–60 - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT07284420RecruitingPhase 2
Testing empasiprubart with efgartigimod for myasthenia gravis
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
Carlsbad, CaliforniaAges 18 years+ - NCT06764017RecruitingPhase 2
New combination therapy for elderly lymphoma unable to handle chemo
This trial tests a new treatment called CHiR for people 70 or older with a type of lymphoma (DLBCL) who are either too frail for standard chemo or choose not to have it. The study aims to see if this therapy can work as a gentler option.
Ningbo, ZhejiangAges 70–100 - NCT07285096Recruiting
New quadruple therapy for H. pylori infection
This trial tests a combination of four medications to treat H. pylori, a bacteria that can cause stomach ulcers and other issues. The goal is to see if this newer therapy works well for people who are infected.
JinanAges 18–70 - NCT07284836RecruitingPhase 2
Chemo directly to liver for breast cancer
This trial tests a new way to give chemotherapy directly to the liver for breast cancer that has spread only there. It's for people who have already tried two or more standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT07287540Recruiting
Anti-inflammatory diet for gum disease treatment
This trial tests whether an anti-inflammatory diet can improve the results of standard gum disease treatment. It is for people diagnosed with periodontitis who are otherwise healthy and do not smoke.
RizeAges 20–65 - NCT07278921Recruiting
Mosunetuzumab for relapsed follicular lymphoma
This trial tests a drug called Mosunetuzumab for people with follicular lymphoma that has come back or stopped responding after at least two previous treatments. It is available through a compassionate use program for those who have no other options.
MilanAges 18 years+ - NCT07280702RecruitingPhase 4
Combination treatment for hard-to-control psoriatic disease
This trial tests adding a new oral medication (deucravacitinib) to your current anti-TNF therapy to see if it helps better control psoriatic arthritis or psoriasis that hasn't improved enough. It may be an option if you still have active symptoms despite being on a stable anti-TNF treatment for at least 6 months.
Dallas, TexasAges 18–65 - NCT07284134RecruitingPhase 3
JS107 vs standard therapy for advanced stomach cancer
This trial tests a new drug, JS107, against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has continued to grow after at least one prior treatment. The cancer must have a specific protein called CLDN18.2 on its cells.
Hefei, AnhuiAges 18 years+ - NCT07282808Recruiting
Focal vs. full prostate treatment study
This trial tests whether targeting only the visible cancer spots on MRI (focal therapy) works as well as treating the whole prostate, for men with small, moderate-risk prostate cancer that hasn't spread.
SingaporeAges 21 years+ - NCT07282821RecruitingPhase 2
Bempedoic acid for polycystic kidney disease
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
Baltimore, MarylandAges 18–60 - NCT07287059Recruiting
Wearable robot and virtual reality for hand recovery after stroke
This study tests if combining a wearable robotic glove with virtual reality exercises can help improve hand function in people who have had a stroke. It may be a good fit if you have some movement in your hand and arm but need more help.
Istanbul, BeykozAges 30–60 - NCT07283757Recruiting
PTSD treatment for incarcerated men and women
This trial tests whether a group therapy for PTSD, called Cognitive Processing Therapy (CPT), helps people in prison. If you have PTSD and are on a waitlist for trauma treatment, this study may offer you a chance to get therapy sooner.
Madison, WisconsinAges 18 years+ - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT07282262RecruitingPhase 2
Ivosidenib for advanced bile duct cancer with IDH1 mutation
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
BeijingAges 18–80 - NCT07282639Recruiting
App-based diabetes education for type 1 diabetes
This study tests an app-based diabetes education program for people with type 1 diabetes. It aims to see if the app can help you manage your blood sugar levels better using insulin pens and a continuous glucose monitor.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for therapy?
- Yes. Clin2 currently lists 7,182 recruiting therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.